Overview
- ISM6331 received Fast Track Designation from the U.S. Food and Drug Administration on July 29, 2026 for treatment of unresectable malignant pleural mesothelioma after prior therapies.
- The designation allows more frequent FDA interactions and could enable rolling submission, Accelerated Approval, or Priority Review if future data meet regulatory criteria.
- ISM6331 is an AI‑designed pan‑TEAD small‑molecule inhibitor that targets TEAD transcription factors in the Hippo signaling pathway, a historically difficult but promising oncology target.
- The drug is being tested in a global, multicenter Phase 1 trial that is evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity, and its first‑in‑human data were accepted for a Rapid Oral presentation at ESMO 2026.
- For patients, the move signals faster regulatory engagement for a treatment in a disease with few options after standard therapy, but efficacy and broader safety remain unproven pending full trial results and the upcoming ESMO presentation.